Tenaya Therapeutics Inc. has announced its strategic priorities and anticipated milestones for 2026. The company plans to build on the positive interim results from its TN-201 gene therapy program by providing longer-term follow-up data for Cohorts 1 and 2 from the MyPEAK-1 trial in adults with MYBPC3-associated hypertrophic cardiomyopathy during the first half of 2026. Additionally, Tenaya expects to report one-year Cohort 1 data and early Cohort 2 data from the RIDGE-1 study of TN-401 for PKP2-associated arrhythmogenic cardiomyopathy in the same timeframe. The company aims to pursue regulatory alignment on pivotal studies for both TN-201 and TN-401, with updates planned for the second half of 2026. Tenaya also intends to use recently raised capital to support the advancement of its clinical programs through these key milestones.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Tenaya Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9622733-en) on January 09, 2026, and is solely responsible for the information contained therein.